Hot Features
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expre... Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.14 | -1.67064439141 | 8.38 | 9.4734 | 7.6425 | 133875 | 8.58505265 | CS |
| 4 | -0.31 | -3.62573099415 | 8.55 | 9.4734 | 7.09 | 118077 | 8.17706792 | CS |
| 12 | 0.83 | 11.2010796221 | 7.41 | 9.4734 | 6.01 | 123035 | 7.56070939 | CS |
| 26 | 7.6968 | 1416.93667158 | 0.5432 | 9.4734 | 0.4601 | 521304 | 2.25507995 | CS |
| 52 | 7.48 | 984.210526316 | 0.76 | 9.4734 | 0.4601 | 848854 | 1.22214236 | CS |
| 156 | 2.9 | 54.3071161049 | 5.34 | 9.4734 | 0.4471 | 864722 | 1.62464378 | CS |
| 260 | -4.14 | -33.4410339257 | 12.38 | 21.87 | 0.4471 | 734332 | 4.88858788 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.